A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed本發明揭示一種尼羅替尼(nilotinib)之固體劑型,其包括:(i)核心,其包括4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]胺基]-N-[5-(4-甲基-1H-咪唑-1-基)-3-(三氟甲基)苯基]苯甲醯胺或其醫藥上可接受之鹽及賦形劑;及(ii)至少一種聚合物,該聚合物塗覆該核心,其中延遲該固體劑型之崩解。